- Dubai's Debt Woes Signal New Era for Creditors
- Fed Audit Would Hurt Economic Prospects: Bernanke
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Tiger Woods Out of Hospital After Accident
- The World's Biggest Debtor Nations
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
Text Size 
Schering-Plough reported higher fourth-quarter earnings in-line with Wall Street expectations.
The Kenilworth, N.J.-based company [SGP
Loading...
()
] posted net income of $182 million, or 12 cents a share, up from $104 million, or seven cents a share, in the year-ago quarter. Earnings were led by strong sales of arthritis treatment Remicade.
Chief executive Fred Hassan told CNBC that the drug company's latest earnings are a further sign that a three-year-old restructuring is having a positive impact.
"We are going into this year with momentum, we are growing very nicely on the top line, we're exerting financial discipline, and our bottom line is growing faster than our top line," Hassan said in an appearance on "Power Lunch" on Monday. "That's a great strategy to have."
Excluding one-time charges of five cents a share, the company earned 17 cents a share, consistent with the Thomson Financial consensus estimate.
Fourth-quarter sales rose 14% from the same quarter a year ago to $2.7 billion, compared with analysts' estimate of $2.53 billion.
Cholesterol drugs accounted for $1.1 billion of those sales. Remicade sales rose 34% from the year-ago period to $337 million.
Barbara Ryan of Deutsche Bank Securities said the company's co-marketing alliance with Merck for cholesterol drug Vytorin has created far greater earnings leverage than the analyst previously expected.
"We continue to believe that the lion's share of the upside in the share price from here may be dependent on Schering-Plough's ability to build on this successful franchise with yet another," Ryan said in a client note Monday.
The analyst reiterated a "hold" rating on Schering-Plough shares with a price target of $24.
Print
Email
- These four sectors will be the next to lead the market.
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- It may be the most unusual guide to business you'll read.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
Data is a real-time snapshot *Data is delayed at least 15 minutes